Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. Also acts as a ubiquitin ligase E3 toward itself and ARRB1. Permits the nuclear export of p53/TP53. Promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein.
Mdm2 Antibody immunohistochemistry of formalin-fixed and paraffin-embedded human prostate carcinoma followed by peroxidase-conjugated secondary antibody and DAB staining.
Western blot of MDM2 (arrow) using rabbit polyclonal Mdm2 Antibody. 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the MDM2 gene (Lane 2) (Origene Technologies).
MDM2 Antibody (Q213) western blot of HepG2 cell line lysates (35 ug/lane). The MDM2 antibody detected the MDM2 protein (arrow).
Western blot of anti-Mdm2 antibody in mouse lung tissue lysate. Mdm2 (Arrow) was detected using purified antibody. Secondary HRP-anti-rabbit was used for signal visualization with chemiluminescence.